BioInfra Co., Ltd. (KOSDAQ:199730)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,270.00
-5.00 (-0.12%)
At close: Apr 24, 2026
Market Cap20.77B -33.3%
Revenue (ttm)23.15B -2.9%
Net Income-9.13B
EPS-1,877.00
Shares Out4.86M
PE Ration/a
Forward PEn/a
Dividend300.00 (6.99%)
Ex-Dividend DateDec 29, 2025
Volume4,716
Average Volume10,193
Open4,225.00
Previous Close4,275.00
Day's Range4,195.00 - 4,270.00
52-Week Range3,200.00 - 6,700.00
Beta0.32
RSI60.36
Earnings Daten/a

About BioInfra

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of gener... [Read more]

Industry Commercial Physical and Biological Research
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 199730
Full Company Profile

Financial Performance

In 2025, BioInfra's revenue was 23.15 billion, a decrease of -2.87% compared to the previous year's 23.83 billion. Losses were -9.13 billion, 129.7% more than in 2024.

Financial Statements